BioNTech SE Cash Flow Quality Index
BioNTech SE cash flow quality index. BioNTech SE (22UA) has a Cash Flow Quality Index of -1.79x as of December 2024. Operating cash flow of €-463.30 Million is below net income of €259.50 Million, suggesting accrual-heavy earnings not yet converted to cash. See how financially flexible is BioNTech SE to measure the company's free cash flow as a share of total liabilities.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of BioNTech SE (2020–2023)
Cash flow quality index of BioNTech SE from 2020 to 2023. Historical Cash Flow Quality Index for BioNTech SE across 4 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore BioNTech SE (22UA) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
BioNTech SE Cash Flow Quality Index by Year (2020–2023)
BioNTech SE cash flow quality index by year from 2020 to 2023. Year-by-year earnings quality comparison for BioNTech SE. For the full cash flow conversion analysis, see BioNTech SE (22UA) cash conversion ratio.
| Year | Quality Index | Operating CF (EUR) | Net Income | YoY Change |
|---|---|---|---|---|
| 2023 | 5.77x | €5.37 Billion | €930.30 Million | ▲ +301.2% |
| 2022 | 1.44x | €13.58 Billion | €9.43 Billion | ▲ +1564.9% |
| 2021 | 0.09x | €889.70 Million | €10.29 Billion | ▲ +109.7% |
| 2020 | -0.89x | €-13.50 Million | €15.20 Million | — |